MMS

Happy 4th of July to our US colleagues, clients, and friends from all of us at MMS! As we celebrate Independence Day, we reflect on the values of freedom and innovation, and we celebrate the spirit of collaboration and excellence that defines our team. Together, we continue to push boundaries, drive innovation, and deliver solutions that make a difference. Wishing you all a safe and joyful holiday filled with fun, family, and fireworks! 🌟 #IndependenceDay #OneMMS

New article! To help Sponsor teams in the overwhelming task of identifying and justifying what is and is not company confidential information (CCI), MMS transparency experts just released a new blog post titled, “Confined Deferrals in Clinical Trial Applications: Anticipating the Revised EU CTR Transparency Rules.” Pre- and post-implementation tips, as well as recommendations for a plan and prepare mindset, are detailed within. Read this: https://hubs.li/Q02FcWKy0 #clinicaltrialtransparency #EUCTR #clinicaltrials

Have you considered combining geospatial and demographic data to aid in site selection for more diverse patient enrollment? It may be worth your time! We've written a detailed article on this topic and how our proprietary Datacise® technology allows users to take their own data and combine it with other data as a background. We detail how multiple layers of data can be displayed simultaneously with near-limitless customization options. This can all be accomplished in a matter of weeks, whereas other tools can take several months to develop! Read our latest article for more on diversifying your patient enrollment: https://hubs.li/Q02DRSyw0 #Diversity #ClinicalTrials #DEI #Pharma #Biotech #ClinicalData #DataScience

Tomorrow, MMS colleagues will attend the Society for Clinical Data Management (SCDM) Single Day Event in Ahmedabad, India! The event explores the intricacies of Risk-Based Data Management (RBDM), with a goal to help attendees embark on a path towards data excellence. The SCDM Single-Day event for 2024, “RBDM Odyssey – From Foundations to Practice” promises to be an enlightening and transformative experience for all attendees. Register now if you haven’t already and we’ll see you there: https://hubs.li/Q02DGRcH0 #SCDM #India #DataManagement #ClinicalData #SCDMIndia

JUST ANNOUNCED: Our global pharmacovigilance experts are coming together to present a new webinar titled, “The Rising Burden of Pharmacovigilance(PV) Requirements in Early Drug Development.” This webinar will cover: 💡 How PV regulations may affect an early-stage drug development program. 💡 Reporting requirements among global health authorities. 💡 Details on individual case safety reports (ICSRs), aggregate reports, and more. 💡 Processes for signal detection and management. Share this event with your network and register here: https://hubs.li/Q02CYtkh0 #OneMMS #DrugDevelopment #PV #Pharmacovigilance #DrugSafety #Pharmaceuticals

📣 New article alert! We just released, “A Structured Approach to Benefit-Risk Assessment Throughout Product Development in the Pharmaceutical Industry.” Read the full article here 👉 https://hubs.li/Q02CZn2s0 to understand: ✔️ What it is ✔️ What information should be included ✔️ Where it can add value If you have questions about Benefit-Risk Assessments or need support, email us at info@mmsholdings.com, and we’ll connect you with one of our experts. #BenefitRiskAssessment #RiskManagement #REMS #DrugDevelopment #ClinicalResearch

Our session on “A Psychedelic Shift: Assessing the Potential for Nonmedical Use in a Changing Regulatory Landscape” is starting in the next few days and we want to make sure you can attend! Register now if you want to learn: ✔️ The evolution of terminology in psychedelics ✔️ How to assess non-medical use ✔️ Tips for engaging health authorities ✔️ Challenges associated with assessing non-medical use in psychedelics research Share this post with your network and register here: https://hubs.li/Q02CBWqm0 #OneMMS #Psychedelics #DrugDevelopment #Regulatory #Pharmaceuticals

When approaching a regulatory submission to the FDA, EMA, or other global health authorities, you need the right data-focused clinical research organization that will consistently produce cohesive, quality focused, and scientifically accurate documents! This is MMS. Click the link 👇below to read case studies, review whitepapers, and learn why Sponsors say “From day one, we were impressed with the efficient and smart decisions brought forth by MMS to bring this drug to market.” More: https://hubs.li/Q02CcmTZ0 Leave a comment on how you feel working with or for MMS! 💬 #OneMMS #pharma #drugdevelopment

Thank you Aine Hanly, Peter Hutt, Vikram Karnani & Uma Sharma for a productive conversation on the ups and downs of regulatory and preparing for success!

In preparation for what promises to be an exciting three days at PSI 2024 in Amsterdam, Principal Biostatistician Japie Lowings will be presenting on the current state (and future) of external data in clinical trials on Monday, June 17th. Our team would be delighted to connect with you throughout the event and invite you to join Japie and Lucy Sutton, VP of Account Management, at booth #19 to learn more about: • Where external data are used in clinical trials - the pros and cons • Statistical methods used for external controls • Future use cases in the making, and • How our #OneMMS global team of experts can accelerate your research journey - applying innovative Biometrics solutions, executed with precision and a shared sense of purpose Preview Japie's poster here and feel free to ping us directly with any questions for our biometrics experts: https://hubs.li/Q02BGPMZ0 We look forward to seeing you there! #biometrics #clinicaldata #RWD #RWE #pharma